Blog

Laura Bukavina: NTACT residual disease test presented by Phillip Abbosh

Photo collage of Laura Bukavina and Phillip Abbosh

Jul 4, 2024, 13:06

Laura Bukavina: NTACT residual disease test presented by Phillip Abbosh

Laura Bukavina, Urologic Oncologist at Cleveland Clinic, shared on X:

“The NTACT residual disease test, eloquently presented by Phillip Abbosh published in JCO Precision Oncology. Remarkably, over 50% of patients without visible residual disease had positive mutations, indicative of field cancerization—mutations present in adjacent normal tissue WITHOUT cancer. NTACT demonstrated 91% sensitivity and 82% accuracy.”

Read further.
Source: Laura Bukavina/X

cancer cancer mutations Cleveland Clinic field cancerization JCO Precision Oncology Laura Bukavina NTACT OncoDaily Oncology oncology research Phillip Abbosh Precision Medicine residual disease test Urologic Oncologist

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage